Copland, D A <br/><br/>
Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.  [electronic resource] 

 -  Clinical and experimental immunology  Mar 2010 
 - 303-14 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2249 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2249.2009.04070.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anaphylatoxins--immunology<br/>Animals<br/>Antibodies, Monoclonal--immunology<br/>Antigens, CD--immunology<br/>Autoimmune Diseases--drug therapy<br/>Complement Activation--drug effects<br/>Complement C5--antagonists & inhibitors<br/>Complement Membrane Attack Complex--immunology<br/>Disease Models, Animal<br/>Inflammation--drug therapy<br/>Interferon-gamma--immunology<br/>Mice<br/>Nitric Oxide--immunology<br/>Rats<br/>Retinitis--drug therapy<br/>Severity of Illness Index<br/>Signal Transduction--drug effects<br/>Uveitis--drug therapy